Entering text into the input field will update the search result below

EyePoint says its wet AMD therapy posed no serious adverse events in early study

Oct. 12, 2021 3:37 PM ETEyePoint Pharmaceuticals, Inc. (EYPT) StockBy: Dulan Lokuwithana, SA News Editor
  • Citing three-month safety data from an early-stage trial, EyePoint Pharmaceuticals (EYPT +6.3%) announced that EYP-1901, a potential twice-yearly treatment for wet age-related macular degeneration (wet AMD), caused no serious adverse events (SAEs) in patients.
  • The data were included in a presentation

Recommended For You

More Trending News

About EYPT Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
EYPT--
EyePoint Pharmaceuticals, Inc.